Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia : results of the 2011 ECCO-EpiCom inception cohort
Copyright © 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved..
BACKGROUND AND AIMS: The aim of the present study was to validate the IBD (inflammatory bowel diseases) incidence reported in the 2010 ECCO-EpiCom (European Crohn's and Colitis Organization-Epidemiological Committee) inception cohort by including a second independent inception cohort from participating centers in 2011 and an Australian center to investigate whether there is a difference in the incidence of IBD between Eastern and Western European countries and Australia.
METHODS: Fourteen centers from 5 Eastern and 9 Western European countries and one center from Australia participated in the ECCO-EpiCom 2011 inception cohort. Patients' data regarding disease type, socio-demographic factors, extraintestinal manifestations and therapy were entered into the Web-based EpiCom database, www.ecco-epicom.eu.
RESULTS: A total of 711 adult patients were diagnosed during the inclusion year 2011, 178 (25%) from Eastern, 461 (65%) from Western Europe and 72 (10%) from Australia; 259 (37%) patients were diagnosed with Crohn's disease, 380 (53%) with ulcerative colitis and 72 (10%) with IBD unclassified. The mean annual incidence rate for IBD was 11.3/100,000 in Eastern Europe, 14.0/100,000 in Western Europe and 30.3/100,000 in Australia. Significantly more patients were diagnosed with complicated disease at diagnosis in Eastern Europe compared to Western Europe (43% vs. 27%, p=0.02).
CONCLUSION: Incidence rates, disease phenotype and initial treatment characteristics in the 2011 ECCO-EpiCom cohort were not significantly different from that reported in the 2010 cohort.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 8(2014), 11 vom: 07. Nov., Seite 1506-15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vegh, Z [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.08.2015 Date Revised 09.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.crohns.2014.06.004 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM239847598 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM239847598 | ||
| 003 | DE-627 | ||
| 005 | 20231224120841.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.crohns.2014.06.004 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0799.xml |
| 035 | |a (DE-627)NLM239847598 | ||
| 035 | |a (NLM)24998983 | ||
| 035 | |a (PII)S1873-9946(14)00187-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vegh, Z |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia |b results of the 2011 ECCO-EpiCom inception cohort |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.08.2015 | ||
| 500 | |a Date Revised 09.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND AND AIMS: The aim of the present study was to validate the IBD (inflammatory bowel diseases) incidence reported in the 2010 ECCO-EpiCom (European Crohn's and Colitis Organization-Epidemiological Committee) inception cohort by including a second independent inception cohort from participating centers in 2011 and an Australian center to investigate whether there is a difference in the incidence of IBD between Eastern and Western European countries and Australia | ||
| 520 | |a METHODS: Fourteen centers from 5 Eastern and 9 Western European countries and one center from Australia participated in the ECCO-EpiCom 2011 inception cohort. Patients' data regarding disease type, socio-demographic factors, extraintestinal manifestations and therapy were entered into the Web-based EpiCom database, www.ecco-epicom.eu | ||
| 520 | |a RESULTS: A total of 711 adult patients were diagnosed during the inclusion year 2011, 178 (25%) from Eastern, 461 (65%) from Western Europe and 72 (10%) from Australia; 259 (37%) patients were diagnosed with Crohn's disease, 380 (53%) with ulcerative colitis and 72 (10%) with IBD unclassified. The mean annual incidence rate for IBD was 11.3/100,000 in Eastern Europe, 14.0/100,000 in Western Europe and 30.3/100,000 in Australia. Significantly more patients were diagnosed with complicated disease at diagnosis in Eastern Europe compared to Western Europe (43% vs. 27%, p=0.02) | ||
| 520 | |a CONCLUSION: Incidence rates, disease phenotype and initial treatment characteristics in the 2011 ECCO-EpiCom cohort were not significantly different from that reported in the 2010 cohort | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Validation Study | |
| 650 | 4 | |a Inception cohort | |
| 650 | 4 | |a Incidence | |
| 650 | 4 | |a Inflammatory bowel diseases | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Steroids |2 NLM | |
| 650 | 7 | |a Mesalamine |2 NLM | |
| 650 | 7 | |a 4Q81I59GXC |2 NLM | |
| 700 | 1 | |a Burisch, J |e verfasserin |4 aut | |
| 700 | 1 | |a Pedersen, N |e verfasserin |4 aut | |
| 700 | 1 | |a Kaimakliotis, I |e verfasserin |4 aut | |
| 700 | 1 | |a Duricova, D |e verfasserin |4 aut | |
| 700 | 1 | |a Bortlik, M |e verfasserin |4 aut | |
| 700 | 1 | |a Avnstrøm, S |e verfasserin |4 aut | |
| 700 | 1 | |a Vinding, K Kofod |e verfasserin |4 aut | |
| 700 | 1 | |a Olsen, J |e verfasserin |4 aut | |
| 700 | 1 | |a Nielsen, K R |e verfasserin |4 aut | |
| 700 | 1 | |a Katsanos, K H |e verfasserin |4 aut | |
| 700 | 1 | |a Tsianos, E V |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, L |e verfasserin |4 aut | |
| 700 | 1 | |a Schwartz, D |e verfasserin |4 aut | |
| 700 | 1 | |a Odes, S |e verfasserin |4 aut | |
| 700 | 1 | |a Lupinacci, G |e verfasserin |4 aut | |
| 700 | 1 | |a De Padova, A |e verfasserin |4 aut | |
| 700 | 1 | |a Jonaitis, L |e verfasserin |4 aut | |
| 700 | 1 | |a Kupcinskas, L |e verfasserin |4 aut | |
| 700 | 1 | |a Turcan, S |e verfasserin |4 aut | |
| 700 | 1 | |a Tighineanu, O |e verfasserin |4 aut | |
| 700 | 1 | |a Mihu, I |e verfasserin |4 aut | |
| 700 | 1 | |a Barros, L F |e verfasserin |4 aut | |
| 700 | 1 | |a Magro, F |e verfasserin |4 aut | |
| 700 | 1 | |a Lazar, D |e verfasserin |4 aut | |
| 700 | 1 | |a Goldis, A |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez, A |e verfasserin |4 aut | |
| 700 | 1 | |a Hernandez, V |e verfasserin |4 aut | |
| 700 | 1 | |a Niewiadomski, O |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, S |e verfasserin |4 aut | |
| 700 | 1 | |a Langholz, E |e verfasserin |4 aut | |
| 700 | 1 | |a Munkholm, P |e verfasserin |4 aut | |
| 700 | 1 | |a Lakatos, P L |e verfasserin |4 aut | |
| 700 | 0 | |a EpiCom-group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 8(2014), 11 vom: 07. Nov., Seite 1506-15 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2014 |g number:11 |g day:07 |g month:11 |g pages:1506-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.crohns.2014.06.004 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2014 |e 11 |b 07 |c 11 |h 1506-15 | ||